



Docket No. ORT-1554

030

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#7

Applicants : Ronghui Lin et al.

Serial No. : 10/029,750

Art Unit: unknown

Filed : December 21, 2001

Examiner: unknown

For : Substituted triazole diamine derivatives as kinase inhibitors

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope addressed
to: Assistant Commissioner for Patents, Washington, D.C. 20231 on

September 27, 2002

(Date)

Myra H. McCormack

Name of applicant, assignee, or Registered Representative

(Signature)

September 27, 2002

(Date of Signature)

Hon. Commissioner for Patents
Washington, D.C. 20231
ATTENTION OF LICENSING AND REVIEW

Declaration in response to a notice of patent application being
"useful in the production or utilization of special nuclear
material or atomic energy" pursuant to 42 U.S.C. § 2182.

Dear Sir:

In response to the notice of patent application being "useful in the production or utilization of special nuclear material or atomic energy" pursuant to 42 U.S.C. § 2182, the time for responding being September 29, 2002, Applicants Representative submits the following declaration prepared by the inventors of record of the above-referenced patent application:

We, Peter J. Connolly, Stuart Emanuel, Robert H. Gruninger, Shenlin Huang, Ronghui Lin, Steven A. Middleton and Steven K. Wetter, all inventors of the above-referenced patent application and employees of Johnson & Johnson Pharmaceutical Research and Development, LLC, having a principal place of business at 1000 U.S. Route 202, Box 3000, Raritan, New Jersey 08869-0602 declare and state as follows:


1. We, Ronghui Lin, Peter J. Connolly, Steven K. Wetter, Shenlin Huang, Stuart Emanuel, Robert H. Gruninger and Steven A. Middleton, are the inventors of the above-referenced patent application entitled "Substituted triazole diamine derivatives as kinase inhibitors", U.S. Patent Application No. 10/029,750, filed on December 21, 2001.
2. The above referenced patent application was made, prepared and filed with the assistant of our Legal Representative as employees of Johnson & Johnson Pharmaceutical Research and Development, LLC, an affiliate of Ortho-McNeil Pharmaceuticals, Inc., one of the Johnson & Johnson Family of Companies.
3. The invention was made within the scope of our employment duties, during working hours with the use of facilities, equipment, materials, funds, information and services of Johnson & Johnson Pharmaceutical Research & Development, LLC.
4. To the best of our knowledge and belief, the invention was not made or conceived in the course of, or in connection with or under the terms of any contract, subcontract or arrangement

entered into with or for the benefit of the United States Atomic Energy Commission or its successors; Energy Research and Development Administration or the Department of Energy nor was the invention made (conceived or first actually reduced to practice) under nor is there any relationship of the invention to the performance of any work under any contract of the National Aeronautics and Space Administration.

5. The present invention relates to pharmaceutically active compounds useful for controlling diseases, such as for example, cancer.
6. The undersigned declare further that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.


Signed this day of September, 2002

Respectfully submitted,



Peter J. Connolly


Date: 9/26/2002




Stuart Emanuel

Date: 9-26-2002


Robert H. Gruninger

Date: 9-27-2002

Shenlin Huang

Date: 9/26/2002

Ronghui Lin

Date: 9/26/2002

Steven A. Middleton

Date: 9-26-2002

Steven K. Wetter

Date: 9/26/02

Respectfully submitted,

Myra H. McCormack
Attorney for Applicants
Reg. No. 36,602Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-6932
Sept 27, 2002